timeline
three decades of Kode Technology
From blood-group glycolipids to synthetic Function-Spacer-Lipid constructs, kodecyte products and Kode Immunoeducers for cancer.
Kode Technology timeline: from R&D tools to immunoeducers
- Kode Biotech — the platform
- Kode Agalimmune — AGI-134
- KodeRx — K5K
- Kode Veterinary Sciences — Kv9
Natural glycolipids · 1988–2002
- 1988
Stephen Henry publishes his first research on blood-group glycolipids: the science that Kode Technology evolved from.
- 1996
Stephen Henry begins using purified natural glycolipids to modify red cells, and makes a prototype quality-control system for blood banks.
- 1999
The technology is named KODE.
Synthetic FSL constructs · 2003–today
- 2003
The first working synthetic Function-Spacer-Lipid (FSL) construct, on 26 August: the birth of Kode Technology.
- 2004
First patent filed, for synthetic membrane anchors.
- 2005
The first kodecyte product, CSL Biosciences' Securacell™ blood-group quality controls, reaches the market. FSL-Galili, the construct later developed as AGI-134, is first made.
A platform for almost any molecule · 2007–today
- 2007
The CMG spacer extends FSL constructs beyond sugars to peptides and many other molecules.
- 2008
FSL-biotin, a universal tool for attaching avidin-linked probes to surfaces.
- 2009
Peptide kodecytes reach the market: AbtechCell™ III and Phenocell™ C, for blood-group antibody screening.
- 2010
FSL constructs are inkjet-printed onto paper to map antibodies.
- 2010
FSL constructs become available worldwide through the Sigma-Aldrich catalogue (now MilliporeSigma).
- 2014
Dr Uri Galili finds that FSL-Galili outperforms the natural glycolipid he was using in cancer research.
- 2015
Agalimmune licenses Kode Technology to develop FSL-Galili as a cancer immunotherapy.
- 2017
A second FSL-Galili patent, with Kode Biotech inventors.
- 2022
AGI-134, a Gen 2 KIE, completes a Phase 1/2a study in 38 late-stage human patients.
- 2023
The Kode Technology Illustrated Technical Manual is published, covering all known Kode Technology data.
- 2025
Stephen Henry is awarded a DSc by the University of Auckland for his thesis on Kode Technology.
- Today
Kv9, a Gen 3 KIE for veterinary cancer, is in clinical trials.
- Today
K5K, a Gen 3 KIE for human cancer, is in pre-clinical development.
The science: read the full story
Stephen Henry's DSc thesis and the Technical Manual tell the full story of Kode Technology.